Compare · Head-to-head
Kisspeptin vs Melanotan II.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Kisspeptin, then use the table to confirm fit.
Kisspeptin is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Kisspeptin
Upstream regulator of reproductive axis (GnRH/LH/FSH). FDA-flagged for compounding concerns.
01 · At a glance
| Decision factor | Kisspeptin | Melanotan II |
|---|---|---|
| Primary fit | sexual health & libido research where you want a clear starting point | skin & hair and sexual health & libido comparisons |
| Evidence | Tier B | Tier C |
| Risk | medium | high |
| Experience level | advanced | advanced |
| Budget tier | premium | budget |
| Administration route | intravenous, subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | Kisspeptin | Melanotan II |
|---|---|---|
| Goal fit | Sexual Health & Libido | Skin & Hair, Sexual Health & Libido |
| What users compare it for | LH/FSH axis stimulation; fertility research applications. | Pigmentation changes (tanning); sexual arousal effects. NOT a controlled therapeutic product. |
| Onset timeline | Acute LH response within ~45 minutes; fertility endpoints context-specific. | Pigmentation changes can occur quickly; adverse events can be acute. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | Kisspeptin | Melanotan II |
|---|---|---|
| Adverse effects | FDA: limited safety data, immunogenicity concerns for compounding. | FDA cites serious adverse events: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, priapism. Immunogenicity/impurity concerns. |
| Contraindications | No formal label; high endocrine interaction potential. | High risk across the board; unlicensed and unapproved. |
| Interaction notes | High endocrine interaction potential with GnRH analogues and gonadotropins. Do not provide stacking guidance. | Unknown; risk may increase with UV exposure behaviors and stimulant-like exposures. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA compounding caution | FDA compounding caution |
| WADA status | WADA S2 | Status unclear |
04 · Age & monitoring
| Decision factor | Kisspeptin | Melanotan II |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Kisspeptin | Melanotan II |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | $80.00 |
| Estimated monthly cost | No reliable estimate yet | $53.33 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | Kisspeptin | Melanotan II |
|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Better as a standalone decision | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.